HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anti-androgen treatment increases circulating ghrelin levels in obese women with polycystic ovary syndrome.

Abstract
In a previous study we were the first to describe a negative correlation between circulating ghrelin concentrations and androgen levels in human plasma, suggesting an interaction between ghrelin and the endocrine regulation of reproductive physiology. We now investigated a potential direct regulatory influence of circulating androgens on plasma ghrelin levels. Fourteen obese women with polycystic ovary syndrome (PCOS) on a hypocaloric diet were randomly assigned to treatment groups (open-labeled design), receiving either placebo (no.=7) or the antiandrogen flutamide (no.=7) for 6 months. Anthropometry, visceral (VAT) and subcutaneous (SAT) adipose tissue (quantified by computerized tomography), plasma hormone levels, insulin sensitivity indexes (Quantitative Insulin-Sensitivity Check Index-QUICKI) and Homeostatic Model Assessment applied to the oral glucose tolerance test (HOMA(OGTT)) were evaluated at baseline and at the end of the study. Body weight decreased and insulin resistance indexes improved in both groups. A tendency toward a greater loss of VAT was observed in the flutamide group. Only in the flutamide group was a significant reduction of androgens levels observed. Plasma ghrelin levels significantly increased following treatment with flutamide, while ghrelin remained unchanged in the placebo group. We observed a negative correlation between changes of ghrelin levels and changes of androgen plasma concentration in the flutamide-treated group. In the same group a positive correlation was found between plasma ghrelin changes and insulin sensitivity as expressed by HOMA(OGTT). Analysis in a multiple regression model, however, showed that plasma ghrelin changes were mainly due to changes of androgen levels rather than improved insulin sensitivity. We, therefore, conclude that androgens are independent modulators of circulating ghrelin concentrations.
AuthorsA Gambineri, U Pagotto, M Tschöp, V Vicennati, E Manicardi, A Carcello, M Cacciari, R De Iasio, R Pasquali
JournalJournal of endocrinological investigation (J Endocrinol Invest) Vol. 26 Issue 7 Pg. 629-34 (Jul 2003) ISSN: 0391-4097 [Print] Italy
PMID14594113 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Androgen Antagonists
  • Blood Glucose
  • Ghrelin
  • Gonadal Steroid Hormones
  • Hormones
  • Peptide Hormones
  • Testosterone
  • Androstenedione
  • Flutamide
Topics
  • Adult
  • Androgen Antagonists (adverse effects, therapeutic use)
  • Androstenedione (blood)
  • Blood Glucose (metabolism)
  • Body Composition (drug effects, physiology)
  • Body Weight (drug effects, physiology)
  • Female
  • Flutamide (adverse effects, therapeutic use)
  • Ghrelin
  • Glucose Tolerance Test
  • Gonadal Steroid Hormones (blood)
  • Hormones (blood)
  • Humans
  • Obesity (blood, complications)
  • Peptide Hormones (blood)
  • Polycystic Ovary Syndrome (blood, complications, drug therapy)
  • Testosterone (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: